Cancer News: Leukemia and lymphoma

First gene therapy approved, for acute lymphoblastic leukemia

The US FDA has approved the first gene therapy for use against a type of blood cancer in the United States.

Some leukemia patients may be able to safely stop their treatment

According to new research, some chronic myeloid leukemia (CML) patients may benefit from stopping their Tyrosine Kinase Inhibitor (TKI) treatments.

Chemotherapy seems helpful in patients with follicular lymphoma

Chemotherapy following radiotherapy can improve progression-free survival (PFS) in patients with follicular lymphoma.

Complete response for lymphoma patients with T-cell therapy

Advanced non-Hodgkin lymphoma ((NHL) patients receiving T-cell treatment, JCAR014 and chemotherapy had a complete response, new data show.

Novel drugs expand treatment options for ALL patients

Key findings of the studies including ofatumumab, ponatinib, liposomal vincristine and reduced-intensity therapy for the treatment of ALL patients.

Updates on therapy options for older AML & CLL patients

Promising results from treatment options for older patients with acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL).

Venetoclax promising for acute myelogenous leukemia

Venetoclax induced promising outcomes to acute myelogenous leukemia patients whose disease had relapsed or was resistant to chemotherapy, a trial shows.

Mantle cell lymphoma: lenalidomide gets EU approval

REVLIMID® (lenalidomide) received approval by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Hodgkin lymphoma: closer to cure with immunotherapy

Hodgkin lymphoma patients remained disease-free for over five years after being treated with the immunotherapy brentuximab vedotin, new data shows.

FDA approves molecular diagnostic for chronic myeloid leukemia

US regulator approved the marketing of a molecular diagnostic test measuring BCR-ABL levels in patients with chronic myeloid leukemia (CML).

Immunotherapy blinatumomab brings hope to ALL patients

Immunotherapy drug blinatumomab extended patients life with relapsed acute lymphoblastic leukemia when compared to chemotherapy.

Ibrutinib gets EU approval for newly diagnosed CLL

EU regulators approved ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).

Nivolumab gets US accelerated approval for Hodgkins lymphoma

US regulators granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma.

FDA approves new targeted therapy for CLL

US regulators approved AbbVie’s drug venetoclax to treat patients with previously treated chronic lymphocytic leukemia.

Assessing treatment in Hodgkin Lymphoma with PET-CT

Positron emission tomography-computed found to be a new standard for staging patients with Hodgkin lymphoma as well as for assessment of treatment response.

Obinutuzumab gets FDA’s green light for follicular lymphoma

US regulators have approved obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma.

Childhood Hodgkin's lymphoma survivors are at risk of breast cancer

Childhood Hodgkin's lymphoma survivors are at risk of breast cancer say researchers, adding that early screening reduces risk of breast cancer death.

US regulators grant breakthrough therapy for AML treatment

Novartis’ investigational drug, midostaurin, received breakthrough therapy designation for US regulators for acute myeloid leukemia.

Childhood leukemia survivors at risk for learning problems

Pediatric acute lymphoblastic leukemia patients treated with chemotherapy alone remain at risk for attention and learning problems later, researchers report.

Arzerra gets US approval against chronic lymphocytic leukemia

US regulators approved Arzerra, to be used as an extended treatment against recurrent or progressive chronic lymphocytic leukemia.

Post-treatment care for young Hodgkin lymphoma survivors

A new study identifies the gaps in post-treatment care for adolescent and young-adult Hodgkin lymphoma survivors.

Linking breast cancer treatment and leukemia

Breast cancer survivors at risk of developing leukemia due to chemotherapy and/or radiation share certain characteristics, a new analysis shows.

Experimental drug improves survival in high-risk AML patients

The drug Midostaurin added to standard chemotherapy improved survival in patients with acute myeloid leukemia carrying mutations in the FLT-3 gene, scientists report.

Blinatumomab brings hope to acute lymphoblastic leukemia patients

Blinatumomab proved to be efficient and safe for the treatment of adult patients with acute lymphoblastic leukemia.

Imbruvica shows better results than chemo in leukemia patients

Chronic lymphocytic leukemia patients decreased more the risk of death when treated with the cancer drug Imbruvica instead of the chemotherapy chlorambucil.

Best treatment option for breast implant-associated cancer

Complete surgical excision proved to be the best treatment for breast implant-associated anaplastic large-cell lymphoma patients as it led to low recurrence rates.

New treatment for acute lymphoblastic leukemia approved in EU

EU regulators approved blinatumomab for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia.

Combination therapy gives hope to mantle cell lymphoma patients

Patients with mantle cell lymphoma benefited from the drug combination of rituximab plus lenalidomide, a new study shows.

Vemurafenib appears effective in hairy cell leukemia

A short course of oral vemurafenib was found to be highly effective in patients with relapsed/refractory hairy cell leukemia, two separate, phase 2 studies reveal.

Conditional European approval for a rare blood cancer drug

The European health regulators conditionally approved Blincyto, a treatment for acute lymphoblastic leukemia (ALL), a rare blood cancer.

Login to your account

Did you forget your password?